Lantern Pharma Achieves Milestone Towards Development Of Molecular Diagnostic For Use In Oncology Clinical Trials For Patient Selection And Stratification With Drug Candidate LP-184; Confirmed PTGR1 As A Key Biomarker That It Intends To Use To Optimize Patient Selection Based On Potential Tumor Sensitivity To The Drug Candidate LP-184
Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184. The diagnostic is currently based on qRT-PCR (quantitative real-time polymerase chain reaction) technology and is focused on quantifying the amount of PTGR1 RNA in patient tumor samples to assess the potential for sensitivity to Lantern's drug candidate LP-184. The company plans to further develop and validate the assay for its use as a potential tool for patient selection in later stage clinical trials across a broad range of solid tumors that have shown sensitivity to LP-184.